Pittman N, et al. - Authors conducted a systematic review of the evidence for all probable small intestinal bacterial overgrowth (SIBO) treatments in systemic sclerosis (SSc) population. They searched the following databases: MEDLINE, EMBASE and the Cochrane Library, from database inception to 1 January 2017. Octreotide was evaluated in 1 trial, while in the remaining 4 trials they gauged the efficacy of ciprofloxacin, rifaximin, norfloxacin and metronidazole, and the combination of amoxicillin, ciprofloxacin and metronidazole. Findings suggested that for some SSc patients, SIBO could be eradicated with antibiotics.